GDF15 may reflect a systemic deterioration and metabolic alteration: thus, it may be non-specific for the population with AVS: patients here included were indeed substantially free from other severe comorbidities (e.g., cancer, immune disorders, infections) and only selected for having an indication for AVR, precluding an analysis of the specificity of our findings. This evidence concerns the gene GDF15 and cancer.